Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 11/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26256186 | 1.00 | ACE (0.40) | ACEXIAPCYP3A4TSHRTDP1 | |
| SCHEMBL10331862 | 1.00 | ACE (0.40) | ACEXIAPCYP3A4TSHRTDP1 | |
| SCHEMBL12034318 | 1.00 | ACE (0.40) | ACEXIAPCYP3A4TSHRTDP1 | |
| SCHEMBL8358700 | 0.97 | XIAP (0.38) | ACEXIAPCYP3A4TSHRTDP1 | |
| SCHEMBL5832021 | 0.97 | XIAP (0.38) | ACEXIAPCYP3A4TSHRTDP1 | |
| SCHEMBL5832039 | 0.97 | XIAP (0.38) | ACEXIAPCYP3A4TSHRTDP1 | |
| SCHEMBL7372845 | 0.95 | ACE (0.43) | ACEXIAPCYP3A4TSHRTDP1 | |
| SCHEMBL10331868 | 0.95 | ACE (0.43) | ACEXIAPCYP3A4TSHRTDP1 | |
| SCHEMBL7372848 | 0.95 | ACE (0.43) | ACEXIAPCYP3A4TSHRTDP1 | |
| SCHEMBL10332106 | 0.95 | ACE (0.43) | ACEXIAPCYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9061069-B2 | Use of constrained peptide mimic oligomers as vectorization agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-06-23 | — | — | US | disclosed |
| US-9061069-B2 | Use of constrained peptide mimic oligomers as vectorization agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-06-23 | — | — | US | disclosed |
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | UNIVERSITE DE MONTPELLIER I (FR) | 2012-07-19 | — | — | US | disclosed |
| EP-2457896-A1 | Tripeptides as caspase modulators | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | DNPEP, IAPP, VIP | ACE 167/4885XIAP 125/4885CYP3A4 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.